XENETIC BIOSCIENCES, INC. Cash and Restricted Cash
XENETIC BIOSCIENCES, INC. (XBIO) had Cash and Restricted Cash of $6.47 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $6.47M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7.35M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7.88M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4.12M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $6.47M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $7.35M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $7.88M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $4.12M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $4.78M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $5.16M 10-Q · filed 2026-05-12 | |
| 2024-12-31 | $6.17M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $6.84M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $7.30M 10-Q · filed 2025-08-12 | |
| 2024-03-31 | $7.82M 10-Q · filed 2025-05-13 | |
| 2023-12-31 | $8.98M 10-K · filed 2026-03-12 | |
| 2023-09-30 | $9.78M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $10.73M 10-Q · filed 2024-08-13 | |
| 2023-03-31 | $11.99M 10-Q · filed 2024-05-09 | |
| 2022-12-31 | $13.10M 10-K · filed 2025-03-18 | |
| 2022-09-30 | $13.85M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $14.93M 10-Q · filed 2023-08-10 | |
| 2022-03-31 | $16.16M 10-Q · filed 2023-05-11 | |
| 2021-12-31 | $18.24M 10-K · filed 2024-03-21 | |
| 2021-09-30 | $19.70M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $9.28M 10-Q · filed 2022-08-11 | |
| 2021-03-31 | $10.01M 10-Q · filed 2022-05-12 | |
| 2020-12-31 | $11.53M 10-K · filed 2023-03-22 | |
| 2020-09-30 | $7.05M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $8.07M 10-Q · filed 2021-08-12 | |
| 2020-03-31 | $9.37M 10-Q · filed 2021-05-11 | |
| 2019-12-31 | $10.37M 10-K · filed 2022-03-22 | |
| 2019-09-30 | $12.04M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $1.03M 10-Q · filed 2020-08-12 | |
| 2019-03-31 | $2.08M 10-Q · filed 2020-05-14 | |
| 2018-12-31 | $638.12K 10-K · filed 2021-03-16 | |
| 2018-09-30 | $1.68M 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $3.32M 10-Q · filed 2019-08-14 | |
| 2018-03-31 | $3.93M 10-Q · filed 2019-05-13 | |
| 2017-12-31 | $5.60M 10-K · filed 2020-03-26 | |
| 2017-09-30 | $761.26K 10-Q · filed 2018-11-09 | |
| 2017-06-30 | $2.40M 10-Q · filed 2018-08-10 | |
| 2017-03-31 | $4.32M 10-Q · filed 2018-05-15 | |
| 2016-12-31 | $4.11M 10-K · filed 2019-03-29 | $4.05M 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |